SNTI insider filings
Senti Biosciences Holdings, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-23. Screen SNTI transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lu Timothy K — CEO, Director | 1 | — | — | 1 |
| Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | 1 | — | — | 1 |
Recent insider filings — Senti Biosciences Holdings, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-23 | 4 | Lu Timothy K — CEO, Director | Tax withholding (F): 157,312 @ $0 | EDGAR |
| 2026-10-23 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Tax withholding (F): 19,953 @ $0 | EDGAR |
| 2026-03-11 | 4 | Lu Timothy K — CEO, Director | Tax withholding (F): 80,666 @ $0 | EDGAR |
| 2026-03-11 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Tax withholding (F): 10,757 @ $0 | EDGAR |
| 2026-02-03 | 4 | Lu Timothy K — CEO, Director | Tax withholding (F): 4,191 @ $0 | EDGAR |
| 2026-02-03 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Tax withholding (F): 1,384 @ $0 | EDGAR |
| 2025-07-21 | 4 | Baum Bryan Daniel — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Hsiung Feng — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Schulz Fran — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Tang Donald F — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Collins James J. — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Mathers Edward T — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Celadon Partners SPV 24 — 10% owner | Conversion (C): 9,777,000 · Conversion (C): 9,777 (derivative) | EDGAR |
| 2025-03-12 | 4 | New Enterprise Associates 15, L.P. — 10% owner NEA Partners 15, L.P. — 10% owner NEA 15 GP, LLC — 10% owner BASKETT FOREST — 10% owner Florence Anthony A. Jr. — 10% owner Makhzoumi Mohamad — 10% owner SANDELL SCOTT D — 10% owner | Conversion (C): 3,333,000 · Conversion (C): 3,333 (derivative) | EDGAR |
| 2025-03-12 | 4 | BAYER HEALTHCARE LLC — 10% owner Bayer US Holding LP — 10% owner Bayer World Investments B.V. — 10% owner BAYER AKTIENGESELLSCHAFT — 10% owner | Conversion (C): 2,222,000 · Conversion (C): 2,222 (derivative) | EDGAR |
| 2025-03-11 | 4 | Schulz Fran — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Hsiung Feng — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Tang Donald F — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Conversion (C): 33,000 @ $2.25 · Conversion (C): 33 (derivative) @ $2,250 | EDGAR |
| 2025-03-11 | 4 | Cross John Harry III — Chief Financial Officer | Grant/award (A): 174,200 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Collins James J. — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Mathers Edward T — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Lu Timothy K — CEO and Interim PFO and PAO, Director | Grant/award (A): 642,358 @ $0 · Grant/award (A): 1,927,073 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Grant/award (A): 78,363 @ $0 · Grant/award (A): 235,088 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Lu Timothy K — CEO, Director | Sale (S): 3,922 @ $4.07 · Sale (S): 545 @ $4.36 | EDGAR |
| 2025-02-06 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Sale (S): 1,297 @ $4.07 · Sale (S): 182 @ $4.37 | EDGAR |
| 2024-12-11 | 4 | BAYER HEALTHCARE LLC — 10% owner Bayer US Holding LP — 10% owner Bayer World Investments B.V. — 10% owner BAYER AKTIENGESELLSCHAFT — 10% owner | Purchase (P): 2,222 (derivative) · Purchase (P): 3,333,000 (derivative) | EDGAR |
| 2024-12-10 | 4 | Schulz Fran — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Tang Donald F — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Grant/award (A): 33 (derivative) @ $2,250 · Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Collins James J. — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Farokhzad Omid — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Mathers Edward T — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | KNOBELMAN DEBORAH — Chief Financial Officer | Grant/award (A): 101,000 @ $0 · Grant/award (A): 152,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Lu Timothy K — CEO and President, Director | Grant/award (A): 306,000 @ $0 · Grant/award (A): 459,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Rajangam Kanya — Chief Medical & Devt. Officer | Grant/award (A): 101,000 @ $0 · Grant/award (A): 152,000 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Collins James J. — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Farokhzad Omid — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Mathers Edward T — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Berland Susan D — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Lee Philip J — Chief Technology Officer | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | KNOBELMAN DEBORAH — Chief Financial Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Lu Timothy K — CEO and President, Director | Grant/award (A): 630,000 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Rajangam Kanya — Chief Medical & Devt. Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2022-10-04 | 4 | KNOBELMAN DEBORAH — Chief Financial Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2022-07-20 | 4 | Rajangam Kanya — Chief Medical & Devt. Officer | Grant/award (A): 327,750 (derivative) @ $0 | EDGAR |
Recent 8-K events — Senti Biosciences Holdings, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-18 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-10-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-10-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-09-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SNTI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs